Chinese antidepressants market led by Paroxetine

The Chinese antidepressants market is currently very small. In 2012 the industry hit a market value of approximately CNY 3.2 billion, showing a year-on-year increase of 22.6%.

Depression is a set of mood disorders or affective disorders with the main symptom of depression caused by various reasons. It is a set of clinical syndrome or conditions centred by the depression of mood self-experience, which is characterised by chronicity, repeated outbreak and various symptoms such as depressed mood, sorrow and pain, lack of interest and pleasant sensation and no motivation.

It is generally believed that the morbidity of depression is mainly associated with biochemical factors such as 5-HT, DA and NE, genetic factors as well as social and environmental factors.

It is estimated that there are over 30 million depression patients in China, among which more than 90% cannot be promptly diagnosed and treated, causing deterioration of diseases and even serious consequences of committing suicide.

Statistics show that committing suicide becomes an important cause of death among young adults aged between 15 and 34 in China. Among these crowds, depression patients account for about two-thirds.

As mental diseases are on the rise and China is about to enter an aging society, antidepressant drugs are faced with a considerable market potential.

The most widely used anti-depressants in China are Paroxetine with a value market share of approximately 18%, Sertraline with a share of approximately 10%, Fluoxetine with a share of approximately 10% followed by Cipramil and Lexapro with 6.5% and 3% respectively.

With the increasing recognition rate of doctors for depression and people's changes in treatment concepts, it is expected that the future potential of China's antidepressant market is fairly great.

For more information on the Chinese antidepressants market, see the latest research: Chinese Antidepressants Market

Follow us on Twitter @CandMResearch